Lomond Therapeutics

Executive Summary

Lomond Therapeutics is a Boston-based small molecule oncology company spun out of Eilean Therapeutics in 2021, focused on developing first-in-class and best-in-class therapies for hematological malignancies driven by treatment resistance. The company targets fundamental biological pathways implicated in resistant mutations and escape mechanisms, aiming to overcome limitations of existing therapies. Its platform leverages deep expertise in cancer biology to design differentiated small molecules that address unmet needs in relapsed/refractory blood cancers. As a development-stage company, Lomond has not yet disclosed specific pipeline candidates or clinical data, but its strategy centers on precision targeting of resistance-conferring alterations, potentially offering durable responses where current options fail. The focus areas include high-value targets in leukemias, lymphomas, and myelomas, with an emphasis on pathways such as apoptosis regulation and epigenetic modifications. Despite being in early stages, Lomond's scientific foundation and experienced team (spinout from Eilean, a known biotech) position it to advance novel therapeutics toward the clinic. The company has not publicly disclosed funding or valuation; however, its niche focus on resistance mechanisms in hematological cancers aligns with significant unmet medical need and commercial potential. Near-term value hinges on progressing its lead program into preclinical development and securing partnerships or financing to support IND-enabling studies.

Upcoming Catalysts (preview)

• TBDLead candidate nomination and initiation of IND-enabling studies65% success
• TBDSeries A financing round to fund pipeline advancement50% success
• TBDDisclosure of preclinical data at a major oncology conference40% success